Drug Profile
BIIB 118
Alternative Names: BIIB118; PF 5251749; PF-05251749Latest Information Update: 02 Jun 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Biogen; Pfizer
- Class Antidementias; Sleep disorder therapies; Small molecules
- Mechanism of Action Casein kinase 1 epsilon inhibitors; Casein kinase Idelta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Circadian rhythm sleep disorders
Most Recent Events
- 31 Dec 2022 Discontinued - Phase-I for Circadian rhythm sleep disorders in USA (PO)
- 19 Aug 2020 Phase-I clinical trials in Circadian rhythm sleep disorders in USA (PO) before August 2020 (Biogen pipeline, August 2020)
- 01 Jun 2020 Preclinical trials in Circadian rhythm sleep disorders in USA (PO), prior to June 2020 (Biogen pipeline, June 2020)